Get started
Author

Albrecht Gröner

Different Outcomes of Experimental Hepatitis E Virus Infection in Diverse Mouse Strains, Wistar Rats, and Rabbits
2018 · Josephine Schlosser, Lisa Dähnert, et al. · Viruses · 225
PDF
Orthopox Viruses: Infections in Humans
2010 · Georg Pauli, Johannes Blümel, et al. · Transfusion Medicine and Hemotherapy · 115
PDF
Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert® P) in hereditary angioedema: a review
2003 · Jean De Serres, Albrecht Gröner, et al. · Transfusion and Apheresis Science · 108
Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies
2009 · Herbert O. Dichtelmüller, Lothar Biesert, et al. · Transfusion · 105
In vitro amplification and detection of variant Creutzfeldt–Jakob disease PrPSc
2007 · M Jones, AH Peden, et al. · The Journal of Pathology · 100
Improved conformation-dependent immunoassay: suitability for human prion detection with enhanced sensitivity
2003 · A. Bellon, W. Seyfert-Brandt, et al. · Journal of General Virology · 95
Investigations of prion and virus safety of a new liquid IVIG product
2008 · M. Stucki, N. Boschetti, et al. · Biologicals · 71
High‐titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionation
2001 · Thomas Weimer, Sigrid Streichert, et al. · Transfusion · 59
Synthesis of biologically active influenza virus hemagglutinin in insect larvae
1989 · K Kuroda, A Gröner, et al. · Journal of Virology · 57
Identification of two nuclear polyhedrosis viruses from the cabbage moth, Mamestra brassicae (Lepidoptera: Noctuidae)
1980 · Just M. Vlak, Albrecht Gröner · Journal of Invertebrate Pathology · 56
Pathogen inactivation and removal methods for plasma‐derived clotting factor concentrates
2013 · Robert Klamroth, Albrecht Gröner, et al. · Transfusion · 52
PDF
Purity of Spiking Agent Affects Partitioning of Prions in Plasma Protein Purification
2002 · M. Vey, H. Baron, et al. · Biologicals · 50
Nanofiltration as a robust method contributing to viral safety of plasma‐derived therapeutics: 20 yearsʼ experience of the plasma protein manufacturers
2020 · Nathan J. Roth, Herbert O. Dichtelmüller, et al. · Transfusion · 47
PDF
Effective inactivation of a wide range of viruses by pasteurization
2017 · Albrecht Gröner, Connie Broumis, et al. · Transfusion · 40
PDF
Pathogen safety of human C1 esterase inhibitor concentrate
2012 · Albrecht Gröner, Thomas Nowak, et al. · Transfusion · 40
Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses
1997 · J. Hilfenhaus, A. Gröner, et al. · Transfusion · 40
Pathogen safety of plasma‐derived products – Haemate® P/Humate‐P®
2008 · A. GRÖNER · Haemophilia · 36
PDF
Prion removal capacity of plasma protein manufacturing processes
2012 · Kang Cai, Albrecht Gröner, et al. · Transfusion · 31
Safety of Factor XIII Concentrate: Analysis of More than 20 Years of Pharmacovigilance Data
2016 · Cristina Solomon, Wolfgang Korte, et al. · Transfusion Medicine and Hemotherapy · 28
PDF
Distinct Stability States of Disease-Associated Human Prion Protein Identified by Conformation-Dependent Immunoassay
2010 · Young Pyo Choi, Alexander H. Peden, et al. · Journal of Virology · 27
PDF
Identification of a new nuclear polyhedrosis virus from Spodoptera exigua
1981 · Just M. Vlak, Kees Van Frankenhuyzen, et al. · Journal of Invertebrate Pathology · 25
Contribution to safety of immunoglobulin and albumin from virus partitioning and inactivation by cold ethanol fractionation: a data collection from Plasma Protein Therapeutics Association member companies
2011 · Herbert O. Dichtelmüller, Lothar Biesert, et al. · Transfusion · 24
High sensitivity of domestic pigs to intravenous infection with HEV
2018 · Lisa Dähnert, Martin Eiden, et al. · BMC Veterinary Research · 23
PDF
Critical factors influencing prion inactivation by sodium hydroxide
2006 · P. A. Bauman, L. A. Lawrence, et al. · Vox Sanguinis · 23
Reply. Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection.
2008 · A. Groner · Haematologica · 22
PDF
Works count: 83
Citation count: 1,777
H-index: 23
I10-index: 35
Year
Topic
Type